• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Boehringer Ingelheim

Hundred dollar bills flowing out of faucet
Biotech

Boehringer's deal frenzy continues with $570M autoimmune pact

The German pharma is turning to established partner CDR-Life for a new trispecific autoimmune antibody.
Darren Incorvaia Nov 4, 2025 8:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Boehringer returns to Kyowa with €640M pact for autoimmune drug

Oct 30, 2025 6:03am
antibody antibody-drug conjugate antibody drug conjugate ADC

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am
schizophrenia mental health brain neurodegenerative

Boehringer, Click DTx hits phase 3 goal in schizophrenia

Oct 14, 2025 12:08pm
liver

FDA considers new liver trial endpoint, sending MASH shares up

Aug 28, 2025 11:25am
eye eyeball eye art

Boehringer inks another eye disease deal, this time with Palatin

Aug 18, 2025 10:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings